Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR.
暂无分享,去创建一个
I. Sermet-Gaudelus | E. Schneider-Futschik | Jérémy Dana | T. Nguyen-Khoa | M. Girard | M. Le Bourgeois | F. Chédevergne | D. Debray | L. Berteloot | D. Drummond | C. Bailly-Botuha | Mathieu Cornet
[1] B. Strandvik,et al. Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[2] E. Schneider-Futschik,et al. Multiple Reaction Monitoring Mass Spectrometry for the Drug Monitoring of Ivacaftor, Tezacaftor, and Elexacaftor Treatment Response in Cystic Fibrosis: A High-Throughput Method. , 2020, ACS pharmacology & translational science.
[3] P. Burgel,et al. Reduced Intestinal Inflammation With Lumacaftor/Ivacaftor in Adolescents With Cystic Fibrosis , 2020, Journal of pediatric gastroenterology and nutrition.
[4] K. Carson,et al. A longitudinal assessment of non-invasive biomarkers to diagnose and predict cystic fibrosis-associated liver disease. , 2020, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[5] Jérémy Dana,et al. Hepatic manifestations of cystic fibrosis. , 2020, Current opinion in gastroenterology.
[6] D. Caimmi,et al. Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.
[7] C. Flask,et al. Lumacaftor/ivacaftor therapy is associated with reduced hepatic steatosis in cystic fibrosis patients , 2019, World journal of hepatology.
[8] P. Lewindon,et al. Accuracy of Transient Elastography Data Combined With APRI in Detection and Staging of Liver Disease in Pediatric Patients With Cystic Fibrosis. , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[9] B. Linnane,et al. GP274 Liver tests in F508del homozygous cystic fibrosis patients on orkambi , 2019, Abstracts.
[10] I. Sermet-Gaudelus,et al. Predictive factors for lumacaftor/ivacaftor clinical response. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[11] G. Sawicki,et al. Safety, pharmacokinetics, and pharmacodynamics of lumacaftor and ivacaftor combination therapy in children aged 2-5 years with cystic fibrosis homozygous for F508del-CFTR: an open-label phase 3 study. , 2019, The Lancet. Respiratory medicine.
[12] H. Corvol,et al. Modifier genes in cystic fibrosis-related liver disease , 2019, Current opinion in gastroenterology.
[13] P. Böelle,et al. Cystic Fibrosis Liver Disease: Outcomes and Risk Factors in a Large Cohort of French Patients , 2018, Hepatology.
[14] J. Goss,et al. Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension. , 2019, Clinical Gastroenterology and Hepatology.
[15] H. Sokol,et al. Diet‐Induced Dysbiosis and Genetic Background Synergize With Cystic Fibrosis Transmembrane Conductance Regulator Deficiency to Promote Cholangiopathy in Mice , 2018, Hepatology communications.
[16] A. Körner,et al. New pediatric percentiles of liver enzyme serum levels (alanine aminotransferase, aspartate aminotransferase, γ‐glutamyltransferase): Effects of age, sex, body mass index, and pubertal stage , 2018, Hepatology.
[17] Jaap Stoker,et al. MR Spectroscopy-derived Proton Density Fat Fraction Is Superior to Controlled Attenuation Parameter for Detecting and Grading Hepatic Steatosis. , 2017, Radiology.
[18] J. Li,et al. Optimized LC-MS/MS Method for the High-throughput Analysis of Clinical Samples of Ivacaftor, Its Major Metabolites, and Lumacaftor in Biological Fluids of Cystic Fibrosis Patients. , 2017, Journal of visualized experiments : JoVE.
[19] M. Trauner,et al. Cystic Fibrosis–related Liver Disease: Research Challenges and Future Perspectives , 2017, Journal of pediatric gastroenterology and nutrition.
[20] S. Stanojevic,et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. , 2017, The Lancet. Respiratory medicine.
[21] A. Berzigotti,et al. Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy , 2017, Gastroenterology report.
[22] R. Fiorotto,et al. The cystic fibrosis transmembrane conductance regulator controls biliary epithelial inflammation and permeability by regulating Src tyrosine kinase activity , 2016, Hepatology.
[23] T. Kotsimbos,et al. Development of HPLC and LC-MS/MS methods for the analysis of ivacaftor, its major metabolites and lumacaftor in plasma and sputum of cystic fibrosis patients treated with ORKAMBI or KALYDECO. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[24] M. Knowles,et al. Features of Severe Liver Disease With Portal Hypertension in Patients With Cystic Fibrosis. , 2016, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[25] C. Minard,et al. Aspartate aminotransferase to platelet ratio and fibrosis‐4 as biomarkers in biopsy‐validated pediatric cystic fibrosis liver disease , 2015, Hepatology.
[26] Xiaohong Huang,et al. Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. , 2015, The New England journal of medicine.
[27] R. Houwen,et al. Increase of Serum &ggr;-Glutamyltransferase Associated With Development of Cirrhotic Cystic Fibrosis Liver Disease , 2015, Journal of pediatric gastroenterology and nutrition.
[28] Ying Sun,et al. Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.
[29] J. Montaner,et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.
[30] James Rader,et al. Rescue of DeltaF508-CFTR trafficking and gating in human cystic fibrosis airway primary cultures by small molecules. , 2006, American journal of physiology. Lung cellular and molecular physiology.
[31] I. Vlachonikolis,et al. Spleen length in childhood with US: normal values based on age, sex, and somatometric parameters. , 2004, Radiology.
[32] F. Ratjen,et al. Cystic fibrosis , 2003, The Lancet.
[33] G. Erbaş,et al. Normal liver, spleen, and kidney dimensions in neonates, infants, and children: evaluation with sonography. , 1998, AJR. American journal of roentgenology.